On 28 April 2026, Mabwell (Shanghai) Bioscience Co., Ltd. (Mabwell, 2493.HK) successfully listed on the Main Board of the Hong Kong Stock Exchange (HKEx), raising a total of approximately HKD 1.30 billion. CBI is honored to participate in the due diligence work for this IPO Project.

Mabwell is principally engaged in the research and development of new molecular entity drugs. The Company’s business includes the research, development, transfer, technical services for and production and sales of new pharmaceutical and chemical technologies and new pharmaceutical products.

In this IPO project, CBI primarily assisted the sponsor team in conducting due diligence on the company group, its directors, senior management, shareholders, customers, suppliers and banks, etc. In addition to the basic information such as litigation, bankruptcy, winding-up and media records, CBI also assisted the sponsor team in conducting reputation intelligence and related company search. The due diligence project globally covered 7 countries and regions, including China, Hong Kong, Singapore and Canada, etc.